Resources

Welcome to our searchable resource and literature collection on safer supply and related topics.

Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.

 
To examine temporal trends in prescription opioid (PO) injection and to assess its association with hepatitis C virus (HCV) seroconversion among people who inject drugs (PWID).
Original research | 2019
Evidence base, Safer supply, About prescribers
This clinical trial aims to test the feasibility of a service that provides virtual overdose response in order to help prevent deaths in populations that cannot or will not access physical supervised
Other | 2021
Overdose, Harm reduction, Illegal drugs
In September 2020, xylazine was first detected by Toronto’s Drug Checking Service
Original research | 2021
Overdose, Mortality, Harm reduction, Policy/Regulatory, Decriminalization/legalization, Drug checking
Drawing on brainstorming sessions and focus groups that were conducted in the summer of 2011, this paper highlights the experiences of NPA members in their own words.
Original research | 2013
Policy/Regulatory, Wrap-around services, Safer supply, Decriminalization/legalization, Equity, Advocacy, About PWUD, Social services, Outcomes, Peer/PWLLE program involvement, Social benefits, Stigma
Archived webinar | various
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Injecting drugs
Archived webinar | 2020
Clinical guidance, Harm reduction, Safer supply, About pharmacists, About prescribers, Housing
The current study aimed to compare the cost-effectiveness of hydromorphone directly with diacetylmorphine and indirectly with methadone maintenance treatment.
Original research | 2018
Evidence base, Safer supply, Crime, Substitution/OAT
PO diversion is widely regarded as a driver of OD mortality.
Original research | 2021
Harm reduction, Safer supply, About PWUD, Barriers and enablers, Poverty, Diversion
Guidelines | 2017
Clinical guidance, Evidence base, Policy/Regulatory, About prescribers
Guidelines | 2023
Clinical guidance, Policy/Regulatory, About prescribers
We discuss accumulated evidence (Box 1) on social interventions and provide an overview of common primary care–based interventions (Table 1), highlighting their strengths, limitations and feasibility
Lit review | 2021
Clinical guidance, Wrap-around services, Equity, About prescribers, Social services
What is the clinical effectiveness of injectable opioid agonist treatment for patients with opioid dependence?
Lit review | 2020
Mortality, Evidence base, Outcomes, Social benefits
To describe 4-year treatment retention and treatment response among chronic, treatment-resistant heroin-dependent patients offered long-term heroin-assisted treatment (HAT) in the Netherlands.
Original research | 2009
Evidence base, Harm reduction, Safer supply, About prescribers, Outcomes, Illegal drugs
Created in collaboration with peers and providers
Guidelines | 2018
About prescribers, About PWUD, Workplace, Peer/PWLLE program involvement
Commentary | 2021
Policy/Regulatory, Decriminalization/legalization, About prescribers, Hallucinogens/psychedelics
Handout | 2021
Safer supply, Illegal drugs, Diversion

BC safe suply interim guidance for safe supply/COVID-19 risk mitigation during the pandemic

Guidelines | 2022
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Rural/remote, Substitution/OAT, Carries/take-home doses
Guidelines | 2017
Clinical guidance, Policy/Regulatory, About prescribers, SCS/OPS
The cost-effectiveness of Canada's only supervised injection facility has not been rigorously evaluated.
Original research | 2008
Evidence base, Advocacy, Illegal drugs, Social benefits, SCS/OPS

Refine Your Search

Keywords
Format
Region